CD28-Selective Inhibition Prolongs Non-Human Primate Kidney Transplant Survival
B. P. Lovasik, S. C. Kim, L. Higginbotham, W. Wakwe, D. V. Mathews, C. P. Breeden, A. B. Farris, C. P. Larsen, M. L. Ford, S. Nadler, A. B. Adams
This study tests a CD28-selective therapy in non-human primates, showing extended kidney transplant survival compared to belatacept alone.
bioRxiv · May 3, 2023 · PreprintImmunology